  World News (13)
  World Earnings (156)
 USA (336)
 California (187)
 Bay Area (12)
Bay Area Earnings (333)
 North San Mateo County (177)
  Business (87)
 Earnings (21)
 1st Quarter Earnings (3)
 4th Quarter Earnings (2)
Cancer Drug Sales (2)
Rituxan (2)
 2012 (1)
2011 (1)
2009 (1)
2008 (1)
2007 (2)
2006 (4)
2005 (5)
2004 (3)
2003 (3)
South SF (21)
Genentech (21)
 Earnings on Wikipedia
 Earnings on Web
|
|
|
| May.2 |
|
PG&E profit is $233 million after blast expenses For PG&E Corp. investors, the company's latest quarterly earnings report on Wednesday featured a welcome lack of surprises
|
|
| May.4 |
|
Profit down on blast-response costs| PG&E: The company reported sharply lower first-quarter profit, in part because its subsidiary spent $51 million dealing with the blast's aftermath | |
|
|
| Jan.18 |
|
Cell Genesys delisting reprieve extended| South SF: At least 125 public companies that could have been dumped off the Nasdaq due to their rock-bottom share prices are still under reprieve | |
|
|
| Jan.14 |
|
4Q Profit Rises 6 Percent| Genentech: The biotech giant barely scraped past expectations as stock dropped in after-hours trading as sales of a key product also fell below expectations | |
|
|
| Oct.16 |
|
3Q Profit Up 21 % On Cancer Drug Sales| Genentech: The profit rose nearly 21% from a year ago, beating expectations by a penny thanks to stronger-than-expected sales of the Avastin | |
|
| Jan.10 |
|
4Q Earnings Soar 75% Genentech: A strong demand for cancer-fighting drugs fueled a profit increase as company executives shook off doubts
|
|
| Jul.11 |
|
2Q Profit Soars to $531 Million Genentech: The biotechnology company blew past Wall Street expectations with a 79% surge in second quarter earnings
|
| Apr.12 |
|
Profit climbs by 48% in first quarter Genentech: Genentech Inc. raised its full-year earnings growth estimate to as much as 55% over 2005
|
| Jan.12 |
|
Shares tumble Genentech: Shares dropped more than 4% as investors reacted to an earnings report that met analysts' expectations
|
| Jan.11 |
|
Up 64% in quarter after good year Genentech: Earnings per share grew 63 percent to 31 cents as cancer drugs continued to build sales
|
|
| Oct.10 |
|
Big 3rd Quarter Gains Genentech: Genentech Inc. reported a 56% surge in 3rd-quarter net income, fueled by drug sales of its colon cancer drug
|
| Jul.11 |
|
Profits Soar 73% in 2Q| Genentech: The second quarter profit is fueled by continued strong drug sales. The results exceeded the estimate by 4 cents | |
|
| May.24 |
|
Genentech up on drug data Drug for a eye disease showed that it may stabilize or reverse the condition in a clinical trial
|
| Apr.12 |
|
Biotech giant's profit up 61% Genentech: The colon cancer drug Avastin and other cancer drugs boost sales
|
| Jan.10 |
|
Profit surges, misses expectations by 1c Genentech: Biotechnology titan reported a 63% surge in its fourth-quarter profits on strong sales of a string of new drugs
|
|
| Oct.6 |
|
Profits surge on drug sales Genentech: Genentech reported a 52% surge in 3rd-quarter net income, fueled by strong drug sales across its product line
|
| Apr.7 |
|
Profits surge on brisk cancer drug sales Genentech: Biotechnology company yearlong hot streak continued when it reported robust profits for the first quarter
|
| Jan.14 |
|
Profits surge on strong drug sales Genentech: The results, lifted by popular cancer-fighting drugs, beat analysts' expectations
|
|
| Oct.8 |
|
Biotech titan posts higher profits Genentech: Genentech is boosted by continued strong sales of its 2 blockbuster cancer-fighting drugs and a one-time legal settlement
|
| Mar.13 |
|
VaxGen stock soars on forecast Brisbane: The beleaguered biotechnology company improved its revenue forecast by 24%
|
| Jan.15 |
|
Reports continued strong earnings Genentech: Profit in the fourth quarter more than doubled, but a $500 million legal setback detracted from an otherwise rosy year
|
|
Add a favorite (file a bookmark) to North San Mateo County, Earnings Timeline
Please send feedback to: support@mapreport.com
Advertise on North San Mateo County, Earnings Page
XML
|
Bio Tech
Main Event: Profit down on blast-re...